EMA Recommends Extending Indications for Lisocabtagene Maraleucel By Ogkologos - November 12, 2025 201 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence Aiming to Improve Cancer Prevention, ESMO Calls for Strong Policy Measures to Fight the Tobacco Epidemic in Feedback on the EU Tobacco Products and... MOST POPULAR 確診癌症後患者應如何面對悲傷 July 7, 2020 Sister Is There To Comfort Her Little Brother As He Battles... September 10, 2019 Significantly Longer PFS with First-line Pembrolizumab for MSI-H/dMMR mCRC December 3, 2020 Mom’s Topless Photo Is Supposed To Encourage Breastfeeding, But Some Think... March 19, 2019 Load more HOT NEWS Fears breast cancer progress could stall due to COVID-19 backlog A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with... Reunión anual de la ASCO 2021: Inmunoterapia para el melanoma y el... ACHIEVE-2 Results of Oxaliplatin-Based Adjuvant Chemotherapy in Asian Patients with High-Risk...
